OpenURL Connection Search

Select item for more details and to access through your institution.

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.
Published in:
1999
By:
- Ettinger B;
- Black DM;
- Mitlak BH;
- Knickerbocker RK;
- Nickelsen T;
- Genant HK;
- Christiansen C;
- Delmas PD;
- Zanchetta JR;
- Stakkestad J;
- Gluer CC;
- Krueger K;
- Cohen FJ;
- Eckert S;
- Ensrud KE;
- Avioli LV;
- Lips P;
- Cummings SR;
- Multiple Outcomes of Raloxifene Evaluation Investigators;
- Ettinger, B
Publication type:
journal article
Efficacy of Levormeloxifene in the Prevention of Postmenopausal Bone Loss and on the Lipid Profile Compared to Low Dose Hormone Replacement Therapy.
Published in:
Journal of Clinical Endocrinology & Metabolism, 2001, v. 86, n. 2, p. 755, doi. 10.1210/jc.86.2.755
By:
- ALEXANDERSEN, P.;
- RIIS, B. J.;
- STAKKESTAD, J. A.;
- DELMAS, P. D.;
- CHRISTIANSEN, C.
Publication type:
Article
Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study.
Published in:
Osteoporosis International, 2004, v. 15, n. 10, p. 792, doi. 10.1007/s00198-004-1602-9
By:
- Delmas, P.;
- Recker, R.;
- Chesnut, C.;
- Skag, A.;
- Stakkestad, J.;
- Emkey, R.;
- Gilbride, J.;
- Schimmer, R.;
- Christiansen, C.
Publication type:
Article
Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study.
Published in:
Osteoporosis International, 2012, v. 23, n. 6, p. 1747, doi. 10.1007/s00198-011-1773-0
By:
- Miller, P.;
- Recker, R.;
- Reginster, J.-Y.;
- Riis, B.;
- Czerwinski, E.;
- Masanauskaite, D.;
- Kenwright, A.;
- Lorenc, R.;
- Stakkestad, J.;
- Lakatos, P.
Publication type:
Article

Found: 4

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Efficacy of Levormeloxifene in the Prevention of Postmenopausal Bone Loss and on the Lipid Profile Compared to Low Dose Hormone Replacement Therapy.

Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study.

Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study.